271 related articles for article (PubMed ID: 12047490)
1. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
[TBL] [Abstract][Full Text] [Related]
2. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers.
de Meijer A; Vollaard H; de Metz M; Verbruggen B; Thomas C; Novakova I
Clin Pharmacol Ther; 1999 Oct; 66(4):425-30. PubMed ID: 10546927
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
4. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers.
Stichtenoth DO; Wagner B; Frölich JC
J Investig Med; 1997 Feb; 45(2):44-9. PubMed ID: 9084574
[TBL] [Abstract][Full Text] [Related]
5. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
Rinder HM; Tracey JB; Souhrada M; Wang C; Gagnier RP; Wood CC
J Clin Pharmacol; 2002 Aug; 42(8):881-6. PubMed ID: 12162470
[TBL] [Abstract][Full Text] [Related]
6. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis.
Knijff-Dutmer EA; Kalsbeek-Batenburg EM; Koerts J; van de Laar MA
Rheumatology (Oxford); 2002 Apr; 41(4):458-61. PubMed ID: 11961179
[TBL] [Abstract][Full Text] [Related]
7. Effects of nabumetone on prostanoid biosynthesis in humans.
Cipollone F; Ganci A; Panara MR; Greco A; Cuccurullo F; Patrono C; Patrignani P
Clin Pharmacol Ther; 1995 Sep; 58(3):335-41. PubMed ID: 7554708
[TBL] [Abstract][Full Text] [Related]
8. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.
Blain H; Boileau C; Lapicque F; Nédélec E; Loeuille D; Guillaume C; Gaucher A; Jeandel C; Netter P; Jouzeau JY
Br J Clin Pharmacol; 2002 Mar; 53(3):255-65. PubMed ID: 11874389
[TBL] [Abstract][Full Text] [Related]
9. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
[TBL] [Abstract][Full Text] [Related]
10. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
Prieto A; De Barrio M; Martín E; Fernández-Bohórquez M; de Castro FJ; Ruiz FJ; Herrero T; Tornero P; Rubio M
J Allergy Clin Immunol; 2007 Apr; 119(4):960-4. PubMed ID: 17292954
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.
Giuliano F; Ferraz JG; Pereira R; de Nucci G; Warner TD
Eur J Pharmacol; 2001 Aug; 426(1-2):95-103. PubMed ID: 11525777
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
13. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
Van Ryn J; Kink-Eiband M; Kuritsch I; Feifel U; Hanft G; Wallenstein G; Trummlitz G; Pairet M
J Clin Pharmacol; 2004 Jul; 44(7):777-84. PubMed ID: 15199082
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer.
Pairet M; van Ryn J; Schierok H; Mauz A; Trummlitz G; Engelhardt G
Inflamm Res; 1998 Jun; 47(6):270-6. PubMed ID: 9683035
[TBL] [Abstract][Full Text] [Related]
16. The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa.
Tavares IA
Aliment Pharmacol Ther; 2000 Jun; 14(6):795-9. PubMed ID: 10848664
[TBL] [Abstract][Full Text] [Related]
17. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam.
Weber EW; Slappendel R; Durieux ME; Dirksen R; van der Heide H; Spruit M
Eur J Anaesthesiol; 2003 Dec; 20(12):963-6. PubMed ID: 14690098
[TBL] [Abstract][Full Text] [Related]
18. Flurbiprofen and enantiomers in ophthalmic solution tested as inhibitors of prostanoid synthesis in human blood.
van Haeringen NJ; van Sorge AA; Van Delft JL; Carballosa Coré-Bodelier VM
J Ocul Pharmacol Ther; 2000 Aug; 16(4):345-52. PubMed ID: 10977130
[TBL] [Abstract][Full Text] [Related]
19. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
20. NSAIDs, Cox-2 inhibitors, and the gut.
Hayllar J; Bjarnason I
Lancet; 1995 Dec; 346(8990):1629. PubMed ID: 7500770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
